[SCHEDULE 13G] DiaMedica Therapeutics Inc. SEC Filing

Rhea-AI Filing Summary

DiaMedica Therapeutics Inc. (DMAC) received a Schedule 13G disclosing that Leon G. Cooperman may be deemed the beneficial owner of 3,110,220 Voting Common Shares, representing approximately 6.0% of the company's outstanding common shares. That total comprises 2,450,000 shares held directly by Mr. Cooperman and 660,220 shares held directly by The Leon and Toby Cooperman Foundation.

The filing states the ownership percentage is calculated using 51,688,913 shares outstanding as of August 8, 2025, per the issuer's quarterly report. The statement affirms the shares were not acquired to change or influence control of the issuer and lists Edward Levy signing as attorney-in-fact on behalf of Mr. Cooperman.

Positive

• Disclosure of a material stake: Reporting of 3,110,220 shares (approx. 6.0%) exceeds the 5% threshold and provides transparency to the market.
• Clear ownership breakdown: Filing specifies 2,450,000 shares held directly and 660,220 held by The Leon and Toby Cooperman Foundation.
• Passive intent declared: Certification states the shares were not acquired to change or influence control, consistent with Schedule 13G treatment.

Negative

• None.

Insights

Securities Analyst

TL;DR Mr. Cooperman discloses a meaningful 6.0% stake in DMAC, combining personal and foundation holdings.

The filing reports 3,110,220 common shares beneficially owned, made up of 2,450,000 shares held directly and 660,220 held by the Cooperman Foundation, representing 6.0% of 51,688,913 shares outstanding as of August 8, 2025. This level of ownership exceeds the 5% reporting threshold, making the disclosure material for holders and potential activists. The certification indicates the stake is not intended to change control. Investors should note the ownership structure (individual plus foundation) and that the Schedule 13G form implies passive intent under applicable rules.

Corporate Governance Expert

TL;DR A 6% holding by a high-profile investor is material to governance dynamics but the filer asserts passive intent.

The Schedule 13G shows combined voting and dispositive power over 3,110,220 shares with no shared voting or dispositive power reported. The filing's certification states the position is not held to influence control, consistent with a passive investor disclosure rather than an active 13D filing. From a governance standpoint, a concentrated 6% stake can attract attention from management and other shareholders even if declared passive, so transparency via this filing is important. The POA signature and foundation involvement are properly disclosed.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

DiaMedica Therapeutics Inc.

(Name of Issuer)

Voting Common Shares, no par value

(Title of Class of Securities)

25253X207

(CUSIP Number)

07/23/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 25253X207

1

Names of Reporting Persons

Cooperman Leon G.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 3,110,220.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 3,110,220.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

3,110,220.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

6 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: DiaMedica Therapeutics Inc.
(b)	Address of issuer's principal executive offices: 301 Carlson Parkway, Suite 210, Minneapolis, Minnesota, 55305
Item 2.
(a)	Name of person filing: This statement is filed on behalf of Leon G. Cooperman ("Mr. Cooperman"). Mr. Cooperman is engaged in, among other activities, investing for his own account. Mr. Cooperman is married to an individual named Toby Cooperman. Mr. Cooperman is one of the trustees of The Leon and Toby Cooperman Foundation (the "Foundation"), a charitable trust dated December 16, 1981.
(b)	Address or principal business office or, if none, residence: Mr. Cooperman's principal business office address is St. Andrews Country Club, 7118 Melrose Castle Lane, Boca Raton, FL 33496.
(c)	Citizenship: Mr. Cooperman is a United States citizen.
(d)	Title of class of securities: Voting Common Shares, no par value
(e)	CUSIP No.: 25253X207
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: The information required by this item with respect to the Reporting Person is set forth in Rows 5 through 9 and 11 of the cover page to this Schedule 13G. Mr. Cooperman may be deemed the beneficial owner of 3,110,220 Common Shares, which is comprised of: (i) 2,450,000 Common Shares held directly by Mr. Cooperman and (ii) 660,220 Common Shares held directly by the Foundation, which collectively constitute approximately 6.0% of the total number of Common Shares outstanding, calculated based on 51,688,913 Common Shares outstanding as of August 8, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 12, 2025.
(b)	Percent of class: 6.0%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 3,110,220
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 3,110,220
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cooperman Leon G.

Signature:	/s/ Edward Levy
Name/Title:	Edward Levy, Attorney-in-Fact
Date:	08/27/2025

Comments accompanying signature: Duly authorized under POA effective as of August 10, 2016 and filed on August 12, 2016.

FAQ

How many DiaMedica (DMAC) shares does Leon G. Cooperman beneficially own?

The filing states Mr. Cooperman may be deemed the beneficial owner of 3,110,220 common shares.

What percentage of DMAC does Cooperman's holding represent?

The Schedule 13G reports the holding represents approximately 6.0% of common shares outstanding.

How is Cooperman's 3,110,220-share position composed?

It comprises 2,450,000 shares held directly by Mr. Cooperman and 660,220 shares held by The Leon and Toby Cooperman Foundation.

Was the stake reported as intended to influence control of DiaMedica (DMAC)?

No. The filing includes a certification that the securities were not acquired and are not held to change or influence the issuer's control.

What outstanding share count was used to calculate the 6.0% figure?

The ownership percentage is calculated using 51,688,913 common shares outstanding as of August 8, 2025, per the issuer's quarterly report.